Sudhakar Sahoo
Overview
Explore the profile of Sudhakar Sahoo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
433
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rostami-Hodjegan A, Al-Majdoub Z, von Grabowiecki Y, Yee K, Sahoo S, Breitwieser W, et al.
Clin Pharmacol Ther
. 2024 May;
116(3):814-823.
PMID: 38738484
Precision dosing strategies require accounting for between-patient variability in pharmacokinetics (PK), affecting drug exposure, and in pharmacodynamics (PD), affecting response achieved at the same drug concentration at the site of...
2.
Smith V, Lee D, Reardon M, Shabbir R, Sahoo S, Hoskin P, et al.
Int J Mol Sci
. 2023 May;
24(10).
PMID: 37240301
Hypoxia and a suppressive tumour microenvironment (TME) are both independent negative prognostic factors for muscle-invasive bladder cancer (MIBC) that contribute to treatment resistance. Hypoxia has been shown to induce an...
3.
Yang K, Zhang W, Zhong L, Xiao Y, Sahoo S, Fassan M, et al.
Cell Death Differ
. 2023 Apr;
30(6):1533-1549.
PMID: 37041291
Lung cancer is the leading cause of cancer-related deaths worldwide. KRAS is the main oncogenic driver in lung cancer that can be activated by gene mutation or amplification, but whether...
4.
Valpione S, Campana L, Weightman J, Salih Z, Galvani E, Mundra P, et al.
Eur J Cancer
. 2022 Nov;
177:164-174.
PMID: 36347135
Background: Immune cell-driven anti-cancer activity is paramount for effective responses to checkpoint inhibitors (ICB). However, the contribution of the different immune cell subsets in the circulation and within the tumour...
5.
La Montagna M, Shi L, Magee P, Sahoo S, Fassan M, Garofalo M
Cell Death Differ
. 2021 May;
28(9):2673-2689.
PMID: 34040167
AMP-activated protein kinase (AMPK) is a critical sensor of energy status that coordinates cell growth with energy balance. In non-small cell lung cancer (NSCLC) the role of AMPKα is controversial...
6.
Shi L, Magee P, Fassan M, Sahoo S, Leong H, Lee D, et al.
Nat Commun
. 2021 Apr;
12(1):2038.
PMID: 33795683
Wild-type KRAS (KRAS) amplification has been shown to be a secondary means of KRAS activation in cancer and associated with poor survival. Nevertheless, the precise role of KRAS overexpression in...
7.
Monteverde T, Sahoo S, La Montagna M, Magee P, Shi L, Lee D, et al.
Cancer Res
. 2021 Jan;
81(7):1719-1731.
PMID: 33472893
Chromosomal instability (CIN) is a driver of clonal diversification and intratumor heterogeneity, providing genetic diversity that contributes to tumor progression. It is estimated that approximately 80% of solid cancers, including...
8.
Bonavita E, Bromley C, Jonsson G, Pelly V, Sahoo S, Walwyn-Brown K, et al.
Immunity
. 2020 Nov;
53(6):1215-1229.e8.
PMID: 33220234
Inflammation can support or restrain cancer progression and the response to therapy. Here, we searched for primary regulators of cancer-inhibitory inflammation through deep profiling of inflammatory tumor microenvironments (TMEs) linked...
9.
Paliouras A, Buzzetti M, Shi L, Donaldson I, Magee P, Sahoo S, et al.
EMBO Mol Med
. 2020 Jun;
12(7):e11099.
PMID: 32558295
A subset of lung adenocarcinomas is driven by the EML4-ALK translocation. Even though ALK inhibitors in the clinic lead to excellent initial responses, acquired resistance to these inhibitors due to...
10.
Mohan S, Foy V, Ayub M, Leong H, Schofield P, Sahoo S, et al.
J Thorac Oncol
. 2019 Oct;
15(2):216-230.
PMID: 31629061
Introduction: SCLC accounts for approximately 250,000 deaths worldwide each year. Acquisition of adequate tumor biopsy samples is challenging, and liquid biopsies present an alternative option for patient stratification and response...